1
|
Taveira-DaSilva AM, Steagall WK and Moss
J: Lymphangioleiomyomatosis. Cancer Control. 13:276–285. 2006.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Yamazaki A, Miyamoto H, Futagawa T, Oh W,
Sonobe S, Takahashi N, Izumi H, Hirama M, Seyama K and Fukuchi Y:
An early case of pulmonary lymphangioleiomyomatosis diagnosed by
video-assisted thoracoscopic surgery. Ann Thorac Cardiovasc Surg.
11:405–407. 2005.PubMed/NCBI
|
3
|
Chang WY, Cane JL, Blakey JD, Kumaran M,
Pointon KS and Johnson SR: Clinical utility of diagnostic
guidelines and putative biomarkers in lymphangioleiomyomatosis.
Respir Res. 13:342012. View Article : Google Scholar : PubMed/NCBI
|
4
|
Singer CA, Barnett SD, Grubbs J and
Camoretti-Mercado B: MiR-25 targeting tuberous sclerosis complex 1
(TSC1) expression in lymphangioleiomyomatosis cells. In: A63.
Advances in lymphangioleiomyomatosis and tuberous sclerosis: Bench
to Bedside American Thoracic Society,. 187:ppA20272013.
|
5
|
Di Leva G, Garofalo M and Croce CM:
MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI
|
6
|
Lang Q and Ling C: MiR-124 suppresses cell
proliferation in hepatocellular carcinoma by targeting PIK3CA.
Biochem Biophys Res Commun. 426:247–252. 2012. View Article : Google Scholar : PubMed/NCBI
|
7
|
Furuta M, Kozaki KI, Tanaka S, Arii S,
Imoto I and Inazawa J: miR-124 and miR-203 are epigenetically
silenced tumor-suppressive microRNAs in hepatocellular carcinoma.
Carcinogenesis. 31:766–776. 2010. View Article : Google Scholar : PubMed/NCBI
|
8
|
Kim VN, Han J and Siomi MC: Biogenesis of
small RNAs in animals. Nat Rev Mol Cell Biol. 10:126–139. 2009.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Xu X, Li S, Lin Y, Chen H, Hu Z, Mao Y, Xu
X, Wu J, Zhu Y, Zheng X, et al: MicroRNA-124-3p inhibits cell
migration and invasion in bladder cancer cells by targeting ROCK1.
J Transl Med. 11:2762013. View Article : Google Scholar : PubMed/NCBI
|
10
|
Qiu Z, Guo W, Wang Q, Chen Z, Huang S,
Zhao F, Yao M, Zhao Y and He X: MicroRNA-124 reduces the pentose
phosphate pathway and proliferation by targeting PRPS1RPIA
mRNAs in human colorectal cancer cells. Gastroenterology.
149:1587–1598.e11. 2015. View Article : Google Scholar : PubMed/NCBI
|
11
|
Liang YJ, Wang QY, Zhou CX, Yin QQ, He M,
Yu XT, Cao DX, Chen GQ, He JR and Zhao Q: MiR-124 targets Slug to
regulate epithelial-mesenchymal transition and metastasis of breast
cancer. Carcinogenesis. 34:713–722. 2013. View Article : Google Scholar : PubMed/NCBI
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2ΔΔCT method. Methods.
25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
13
|
Koukos G, Polytarchou C, Kaplan JL,
Morley-Fletcher A, Gras-Miralles B, Kokkotou E, Baril-Dore M,
Pothoulakis C, Winter HS and Iliopoulos D: MicroRNA-124 regulates
STAT3 expression and is down-regulated in colon tissues of
pediatric patients with ulcerative colitis. Gastroenterology.
145:842–852.e2. 2013. View Article : Google Scholar : PubMed/NCBI
|
14
|
Zhang J, Lu Y, Yue X, Li H, Luo X, Wang Y,
Wang K and Wan J: MiR-124 suppresses growth of human colorectal
cancer by inhibiting STAT3. PLoS One. 8:e703002013. View Article : Google Scholar : PubMed/NCBI
|
15
|
Gorla-Bajszczak A, Juge-Aubry C, Pernin A,
Burger AG and Meier CA: Conserved amino acids in the ligand-binding
and tau(i) domains of the peroxisome proliferator-activated
receptor alpha are necessary for heterodimerization with RXR. Mol
Cell Endocrinol. 147:37–47. 1999. View Article : Google Scholar : PubMed/NCBI
|
16
|
Young L, Lee HS, Inoue Y, Moss J, Singer
LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, et al:
Serum VEGF-D a concentration as a biomarker of
lymphangioleiomyomatosis severity and treatment response: A
prospective analysis of the multicenter international
lymphangioleiomyomatosis efficacy of sirolimus (MILES) trial.
Lancet Respir Med. 1:445–452. 2013. View Article : Google Scholar : PubMed/NCBI
|
17
|
Shi XB, Xue L, Ma AH, Tepper CG,
Gandour-Edwards R, Kung HJ and deVere White RW: Tumor suppressive
miR-124 targets androgen receptor and inhibits proliferation of
prostate cancer cells. Oncogene. 32:4130–4138. 2013. View Article : Google Scholar : PubMed/NCBI
|
18
|
Ito Y, Inoue A, Seers T, Hato Y, Igarashi
A, Toyama T, Taganov KD, Boldin MP and Asahara H: Identification of
targets of tumor suppressor microRNA-34a using a reporter library
system. Proc Natl Acad Sci USA. 114:3927–3932. 2017. View Article : Google Scholar : PubMed/NCBI
|
19
|
Lam HC, Liu HJ, Baglini CV, Filippakis H,
Alesi N, Nijmeh J, Du H, Lope AL, Cottrill KA, Handen A, et al:
Rapamycin-induced miR-21 promotes mitochondrial homeostasis and
adaptation in mTORC1 activated cells. Oncotarget. 8:64714–64727.
2017. View Article : Google Scholar : PubMed/NCBI
|
20
|
Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH,
Chen SP, Bian XW, Guan XY, Lin MC, Zeng YX, et al: The putative
tumour suppressor microRNA-124 modulates hepatocellular carcinoma
cell aggressiveness by repressing ROCK2 and EZH2. Gut. 61:278–289.
2012. View Article : Google Scholar : PubMed/NCBI
|
21
|
Xie L, Zhang Z, Tan Z, He R, Zeng X, Xie
Y, Li S, Tang G, Tang H and He X: MicroRNA-124 inhibits
proliferation and induces apoptosis by directly repressing EZH2 in
gastric cancer. Mol Cell Biochem. 392:153–159. 2014. View Article : Google Scholar : PubMed/NCBI
|
22
|
Gong X, Wang H, Ye Y, Shu Y, Deng Y, He X,
Lu G and Zhang S: miR-124 regulates cell apoptosis and autophagy in
dopaminergic neurons and protects them by regulating AMPK/mTOR
pathway in Parkinson's disease. Am J Transl Res. 8:2127–2137.
2016.PubMed/NCBI
|
23
|
Goncharova EA, Goncharov DA, Fehrenbach M,
Khavin I, Ducka B, Hino O, Colby TV, Merrilees MJ, Haczku A,
Albelda SM and Krymskaya VP: Prevention of alveolar destruction and
airspace enlargement in a mouse model of pulmonary
lymphangioleiomyomatosis (LAM). Sci Transl Med. 4:154ra1342012.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Mangelsdorf DJ, Ong ES, Dyck JA and Evans
RM: Nuclear receptor that identifies a novel retinoic acid response
pathway. Nature. 345:224–229. 1990. View
Article : Google Scholar : PubMed/NCBI
|
25
|
De Luca LM: Retinoids and their receptors
in differentiation, embryogenesis, and neoplasia. FASEB J.
5:2924–2933. 1991. View Article : Google Scholar : PubMed/NCBI
|
26
|
Varanasi U, Chu R, Huang Q, Castellon R,
Yeldandi AV and Reddy JK: Identification of a peroxisome
proliferator-responsive element upstream of the human peroxisomal
fatty acyl coenzyme A oxidase gene. J Biol Chem. 271:2147–2155.
1996. View Article : Google Scholar : PubMed/NCBI
|
27
|
Pike LS, Smift AL, Croteau NJ, Ferrick DA
and Wu M: Inhibition of fatty acid oxidation by etomoxir impairs
NADPH production and increases reactive oxygen species resulting in
ATP depletion and cell death in human glioblastoma cells. Biochim
Biophys Acta. 1807:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
|
28
|
Samudio I, Harmancey R, Fiegl M,
Kantarjian H, Konopleva M, Korchin B, Kaluarachchi K, Bornmann W,
Duvvuri S, Taegtmeyer H, et al: Pharmacologic inhibition of fatty
acid oxidation sensitizes human leukemia cells to apoptosis
induction. J Clin Invest. 120:142–156. 2010. View Article : Google Scholar : PubMed/NCBI
|
29
|
Minucci S, Horn V, Bhattacharyya N,
Russanova V, Ogryzko VV, Gabriele L, Howard BH and Ozato K: A
histone deacetylase inhibitor potentiates retinoid receptor action
in embryonal carcinoma cells. Proc Natl Acad Sci USA.
94:11295–11300. 1997. View Article : Google Scholar : PubMed/NCBI
|